CYTH Company Profile and Key Details

CYTH has shown sold momentum, gaining 5.97% over the past week and 19.7% over the past quarter, though year-to-date performance is up 22.14%. Short-term trend indicators are bullishly aligned (SMA20 1.45%, SMA50 -8.57%, SMA200 -15.88%). The stock’s 14-day RSI is 47.9 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -59.74% below its high and over 31.02% above its low.

Cyclo Therapeutics, Inc. generated EPS of -$0.90 over the past year. Five-year average earnings growth is -88.22%. The latest quarter delivered EPS of -$0.26. The next quarter is forecast at $nan. Next year's EPS is expected at $38.39. Cyclo Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2024, missed forecasts by 52.94%. The prior quarter beat by 50.0%. Over the last six quarters, Apple has recorded several small beats. These include 9.52% in May 15, 2023.

Cyclo Therapeutics, Inc. has 32.74 million shares outstanding. The public float is 11.51 million shares, elevated short interest at 1.51% of float. This equals 434.12 thousand shares. The short ratio is 5.58 days. Institutional investors hold 22.21% of the float. Insiders own 48.45%. ARMISTICE CAPITAL, LLC holds 15.80 million shares, Rafael Holdings, Inc. has 2.77 million shares and FINE N SCOTT has 329.34 thousand shares.

The stock is currently mid-range between its 52-week high and low $0.55 and $1.62. With a market capitalization of about $23.59 million, Cyclo Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.57). Key stats such as the average daily volume over the past year has been around 1.76 million shares, volume is running light vs its 52-week average. Headquartered in Gainesville, FL, Cyclo Therapeutics, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO N. Scott Fine, the company employs approximately 8 people and listed since May 03, 2000. Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) shares are up 22.14% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cyclo Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.59. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $2.38, suggesting 230.28% upside. Our AI forecast model points to short-term weakness (-25.06% over two weeks), a medium-term fall (-32.0% over three months), and a longer-term gain (51.26% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Cyclo Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -25.06%, with price expected at $0.54 by April 10, 2025, within a range of $0.45 to $0.63 3-Month Outlook: Projected fall of -32.0%, reaching $0.49 by June 25, 2025, with a range of $0.43 to $0.54. 1-Year Outlook: Projected gain of 51.26%, with price at $1.09 by March 27, 2026, within a range of $0.00 to $0.33.

Cyclo Therapeutics, Inc. trades at a P/E ratio of -0.59, slightly below the S&P 500 average, with a price-to-sales ratio of 21.92 and a price-to-book ratio of 2.47 suggesting the stock is closer to book value. The P/FCF stands at -1.46, also above market averages.